11c-methylation |
112 |
13c -labeled tracer |
#557 |
13c mrs |
PS 23-03 |
13c nmr |
PS 23-03 |
13c-labeled tracer |
PS 02-06 |
18f |
PS 05-03 |
18f-fdg |
PS 08-02 |
18f-fdg pet |
127 |
18f-fdg pet/ct |
172 |
18f-fdg-pet |
PS 06-04 |
18f-fluoronaphthol |
#35 |
18f-flurolactate |
PS 08-02 |
18f-fmiso |
177 PS 08-07 |
19f |
PS 08-04 #465 |
19f mri |
PS 08-04 PS 08-04 #395 |
19f-mri |
PS 08-04 126 |
2-nitroimidazole |
PL 07 |
2-photon imaging |
PS 24-03 |
2h fumarate |
PL 05 |
31p magnetic resonance imaging |
#11 |
31p magnetic resonance spectroscopy |
#11 |
3d image registation |
#319 |
3d imaging |
PS 19-03 |
3d live imaging |
111 |
3d live tracking. |
#367 |
3r |
#466 |
5-ht1a receptors |
PS 23-02 |
52-mn |
#92 |
5d ct |
PS 02-02 |
62zn |
PS 05-03 |
68ga |
#40 129 |
68ga-dkfz-psma-11 |
112 |
68ga-dota-cdp1 |
129 |
68gadfo |
129 |
89zr |
PS 09-07 |
90y-dota-psma-d4 |
#311 |
99mtc-mibi |
119 |
99mtc-radiotracer |
113 113 |
[11c]ucb-j |
191 128 |
[18f]cf4 |
PS 08-03 |
[18f]cinacalcet |
112 |
[18f]dpa-714 pet |
#33 PS 21-03 |
[18f]faza |
PL 06 |
[18f]fluda |
#263 130 |
[18f]fluoroform |
112 |
[18f]fluorothymidine |
191 103 |
[18f]frpg |
PS 08-07 |
[18f]fspg |
PS 08-07 |
[18f]ge180 |
PS 21-03 |
[18f]psma-1007 |
100 |
[68ga]-ubi |
129 |
a2ar |
130 |
abdominal aortic aneurysm |
191 PS 08-06 103 |
acetazolamide |
#413 |
acetylcholine |
#325 PS 23-02 |
acini |
PS 08-06 |
acquatic animal imaging |
#45 |
acute cardiomyopathy induced by stress |
130 |
acute respiratory distress syndrome |
178 PS 21-02 |
adenosine |
130 |
adenosine 2a receptor |
102 |
adenosine a2a receptor |
#263 |
adept |
#250 |
administration routes |
#233 |
advanced imaging facilities |
#726 |
affibody |
PS 23-05 |
aging |
#385 |
aif |
PS 08-03 |
akt1 kinase |
129 |
alf-18 |
179 112 |
alk5 |
PS 23-04 |
alpha-emitters |
PS 07-04 |
alpha-synuclein |
128 |
als |
127 |
alternativ animal model |
#320 |
alzheimer |
PS 08-03 |
alzheimer disease |
PS 10-02 |
alzheimer disease model |
102 |
alzheimer model |
102 |
alzheimer' disease |
128 |
alzheimer's disease |
PS 01-05 PS 09-03 102 #237 |
alzheimer's mouse model |
127 |
alzheimer’s disease |
PS 09-03 |
ambroxol |
127 |
amino acids |
113 |
amphipathic peptide |
126 |
amphotericin b |
178 PS 05-04 #257 |
amyloid |
PS 01-05 #222 |
amyloid plaques |
PS 09-03 |
amyloid-beta |
PS 09-03 128 |
anesthesia |
PS 23-02 PS 23-03 #576 PS 24-03 |
aneuploidy |
PL 06 |
angiogenesis |
#357 |
angiography |
PS 23-06 128 |
angiotensin ii |
191 103 |
animal |
PL 06 |
animal model |
PS 01-05 PL 05 130 |
animal study |
#311 |
anthracyclines |
130 |
anti-cancer agents |
#394 |
anti-cancer drug |
101 |
antibiocs |
PS 05-06 |
antibiotics |
178 PS 05-04 |
antibodies |
#654 |
antibody |
PS 05-06 PS 05-06 PL 07 100 139 |
antibody modification |
PL 07 |
antibody-fragments |
#654 |
anticancer |
#346 |
antitumor metal complexes |
105 #216 |
aortic dissection |
103 |
apoe-/- |
191 103 |
apoptosis |
177 PS 06-03 126 |
aptamer |
178 PS 09-02 |
aptamers |
111 |
arftificial intelligence |
PS 08-06 |
arterial tacs |
179 #291 |
arthritis |
#466 |
artifacts |
#54 |
ascending aorta aneurysms |
103 |
asthma mouse model |
#393 |
astrocytes |
127 |
asymmetric radiosynthesis |
113 |
atherosclerosis |
PS 22-05 PS 23-04 PS 08-04 #40 103 104 |
atherosclerotic plaque |
104 |
atlas creation |
109 |
atlas registration |
111 |
au nanocluster |
#206 |
auditory processing |
#591 PS 08-03 |
autism spectrum disorder |
PS 10-02 |
automation |
#163 |
autoradiography |
PS 01-05 PS 01-05 |
avb6 |
101 |
awake |
PS 24-03 PS 24-03 |
axr |
#57 |
aza-bodipy |
139 |
azd2461 |
192 100 |
azd3965 |
PS 08-02 |
background correction |
PS 08-06 |
backscattering |
PL 07 |
bacterial infection |
PS 05-06 |
barrett's oesophagus |
177 PS 09-07 |
basal cell carcinoma |
PL 06 |
basal forebrain cholinergic system |
#325 PS 23-02 |
bbb |
PS 09-02 |
bbmri |
#751 |
beam hardening |
193 #148 |
behavior |
111 #367 |
behaviour |
PS 24-03 |
bevacizumab |
PS 06-03 |
biased agonist |
PS 23-02 |
bicuspid aortic valve |
103 |
bimodal |
177 PS 08-02 |
bimodal imaging |
139 139 |
bimodal mri/pet |
#92 |
bimodality |
179 105 105 |
binding assay |
111 |
biobanking |
#751 |
bioconjugation |
PS 05-03 |
biodistribution |
100 128 |
bioimaging |
#688 #684 #273 #388 #112 |
bioimaging austria |
#746 |
bioluminescence imaging |
#504 |
bioluminescence tomography |
PS 07-04 |
biomarker |
192 PL 05 PS 05-02 #212 #54 |
biomarkers |
100 |
biosensors |
PS 18-06 |
biotin |
111 |
bispidine |
#92 |
bladder segmentation |
100 |
bleomycin |
#576 |
blood brain barrier |
127 |
blood flow |
#374 PS 05-06 |
blood pressure radiotelemetry |
139 |
blood vessels permeability |
#357 |
blood-brain barrier |
128 |
bodipy |
PS 06-05 |
bold oscillations |
109 |
bold-fmri |
PS 22-03 |
bone formation |
104 |
bone healing |
PS 10-02 |
bone model |
PS 09-07 |
boron vectorization |
192 101 |
brain |
PS 05-06 PS 06-04 102 128 |
brain atlas |
109 #416 |
brain cancer |
PL 06 |
brain perfusion |
#374 PS 05-06 |
brain slice |
109 |
brain tumor |
PS 08-03 |
brain tumors |
112 |
brain-targeted delivery system |
112 |
brainstate |
#413 |
breast cancer |
193 PS 19-03 PS 23-05 PS 06-03 PL 06 #58 |
breast imaging |
193 #58 |
breast tissue cancer |
100 |
bronchial wall thickness |
PS 07-04 |
brown adipose tissue |
PS 06-04 |
bruker |
PS 10-02 |
bssfp |
193 #252 PS 02-06 |
burst suppression |
PS 23-02 |
c. elegans |
#385 |
calcification |
PS 05-03 |
calcifications |
PS 21-03 |
calcium |
PS 23-04 PS 08-04 |
calcium fluoreescence imaging |
127 |
calcium imaging |
PS 09-03 |
calibration |
111 |
cancer |
192 PS 22-05 PS 22-05 PS 05-02 100 100 111 126 139 #427 PS 24-02 #618 PS 02-06 |
cancer cell spheroids |
#472 |
cancer imaging |
PS 08-07 PS 08-07 126 |
cancer immunotherapy |
PS 05-02 |
cancer surgery |
193 #197 |
cancer therapy |
101 |
candida albicans |
129 |
caps camera |
PS 23-07 |
carbon monoxide |
#127 |
carbon-11 |
PS 01-02 112 113 |
carbonic anhydrase ix |
PS 08-07 |
cardiac |
105 PS 01-04 |
cardiac function |
PS 10-02 |
cardiac imaging |
PS 21-02 |
cardiac mri |
#205 |
cardiac remodeling |
PS 01-04 |
cardiogenic shock |
PS 09-02 |
cardiomyopathy |
PS 23-04 PS 01-04 |
cardiotoxicity |
130 |
cardiovascular |
112 #686 |
cardiovascular disease |
PS 23-06 103 |
cardiovascular diseases |
#405 |
carotid artery |
193 #457 |
carotid atherosclerosis |
103 |
cd4 t cells |
PS 05-02 |
cd47 |
126 |
cd8 |
#495 |
cd80 |
PS 23-05 |
cell death |
177 PS 06-03 |
cell labelling |
112 |
cell surface receptor |
PS 01-02 |
cell therapy |
105 127 |
cell tracking |
PS 06-05 105 |
cell-penetrating peptides |
PL 07 |
cerebral ischemia |
PS 08-03 PS 09-03 |
cerebral malaria |
#374 PS 05-06 |
cerebral metabolism |
PS 23-03 |
cerebrovascular |
178 PS 09-03 |
cerenkov imaging |
PS 08-07 #181 |
cerenkov luminescence imaging |
193 #197 |
cerenkov luminescence imaging (cli) |
#311 |
cest |
PS 06-04 111 #613 |
cest quantification |
111 |
cest-mri |
111 |
chelation |
#407 |
chemical delivery system |
112 |
chemistry |
PS 05-03 |
chemokine receptor |
PS 22-05 |
chemokines |
PS 22-05 |
chemoresistance |
101 |
chemosensitivity |
PL 06 |
chemotherapeutics |
#394 |
chemotherapy |
101 |
choline metabolism |
#205 |
chronic bronchitis |
PS 07-04 |
chronic pain |
127 |
chronic stage |
127 |
cisplatin |
PL 07 PL 06 #714 |
classification study |
100 |
clemastine |
191 #46 |
click chemistry |
192 PL 07 PL 07 |
click-chemistry |
#321 |
clinical ct |
#25 |
clinical isolates |
130 |
clinical translation |
PS 06-03 PS 24-02 #647 |
clinical trial |
177 PS 23-07 PS 06-03 PS 24-02 |
clinical trials |
177 PS 09-07 139 |
clustering |
111 |
cmr |
191 130 |
cochlea |
109 |
cognition |
PS 24-03 |
coincidence time resolution |
119 |
collagen based scaffold |
128 |
collagen organization |
128 |
collimator |
PS 01-06 |
colon cancer |
PL 06 111 |
colorectal cancer |
PS 06-03 125 |
colorectal cancer subtypes |
PS 05-02 |
companion diagnostics |
PS 06-03 |
compartment modelling |
100 |
compton camera |
PS 08-03 |
computed tomography |
PS 05-04 PS 02-02 |
comulis |
168 #746 |
cone trajectory |
178 PS 23-03 |
confocal |
PL 06 |
congenital hyperinsulinism |
#336 |
conjugated polymer nanoparticles |
#273 #440 #388 |
conjugation |
#150 |
connexin |
#237 |
contrast agent |
176 PS 01-02 #321 #303 104 105 |
contrast agents |
176 PS 08-04 #25 #255 #20 #558 |
contrast enhanced ultrasound |
192 125 |
contrast media |
PS 21-02 |
contrast-enhanced computer tomography |
#222 |
contrast-enhanced ultrasound imaging |
176 PS 06-05 |
copd |
PS 07-04 |
core-modifications |
PS 01-02 |
corioallantoic membrane |
#370 |
coronary arteries |
PS 21-02 |
coronary artery disease |
PS 22-05 |
correlative cryo-imaging |
PS 22-06 |
cost-effectiveness |
172 |
cpg2 |
#250 |
crc mouse models |
PS 05-02 |
crc stratification |
PS 05-02 |
crispr/cas9 |
PL 05 |
croconaine nanoparticles |
PS 08-03 |
crohn's disease |
PS 08-03 |
cryo-em |
#723 |
cryopreservation |
#704 |
csf |
#413 #421 |
csf-1r |
#33 PS 23-05 PS 21-03 |
ct |
PS 01-05 #320 |
ct filters |
111 |
ct imaging |
#393 |
ct-fmt imaging |
PL 06 #275 |
cu-64 |
PL 07 #714 |
cuprizone |
191 #46 |
curprizone |
102 |
cxcr4 |
PS 22-05 PS 22-05 PS 22-05 |
cyanine dyes |
112 |
cyanine-graphene hybrids |
#487 |
cyanines |
#165 |
d2 receptor |
PS 23-02 |
darpins |
125 |
data analysis |
PL 06 |
data processing |
111 |
data quantification |
178 PS 08-06 |
dce |
111 |
dce-mri |
102 |
ddnp |
PS 23-03 |
deconvolution |
111 |
deep learning |
PS 08-06 111 |
deep learning for ct |
PS 02-02 |
default mode network |
#325 PS 23-02 |
demyelination |
191 102 #46 |
dendrimer |
PL 07 |
density |
102 |
desferrioxamine b |
129 |
desferrioxamine derivative |
176 PS 05-03 |
desi |
PS 06-04 #635 |
deuterium |
176 PS 05-02 PS 06-04 |
deuterium metabolic imaging |
PL 05 |
dfo* |
PS 09-07 |
diagnosis |
100 |
differentiation |
100 |
diffusion |
#391 |
dimeric pesin conjugates |
#84 |
disorder strength |
PL 07 |
dispersion |
PS 08-03 |
dnp |
PS 06-04 |
dominant follicle selection |
#357 |
donepezil |
#237 127 |
dopamine |
PL 05 |
dopamine receptors expression changes |
PL 05 |
dosimetry |
111 |
dota |
128 |
down syndrome |
103 127 |
doxorubicin |
125 128 #512 |
dp1tyb model |
127 |
dpa-714 |
PS 23-05 |
dreadds |
#325 PS 23-02 |
drug delivery particles |
#583 |
drug development |
#628 |
drug discovery |
#635 |
drug efficiency evaluation |
#394 |
drug release |
PS 06-05 |
drugs-lipiodol emulsions |
105 |
dti |
191 102 127 |
dual labeling |
PS 23-07 |
dual-isotope imaging |
PS 07-04 |
dual-labeling |
#151 |
dwarf shrimp |
111 #372 #367 |
dwi |
#424 |
dyes |
PS 09-02 |
dynamic acquisition |
PL 06 |
dynamic ct imaging |
PS 02-02 |
dynamic functional connectivity |
102 |
dynamic imaging |
PS 01-06 |
eae nhp |
128 |
early bladder tumour detection |
100 |
early detection |
177 PS 09-07 |
eatris eric |
#684 |
egcg modulation |
103 |
egfr |
PS 23-05 100 113 |
el4 |
#44 PS 02-06 |
elastin-derived peptides |
PS 08-02 |
electrophysiology |
PS 23-02 |
elemental imaging |
PS 05-04 |
embolics |
PS 23-06 |
embryo |
#464 |
emi-137 |
PS 23-07 |
emim 2020 |
#736 PS 05-03 PS 23-07 PS 08-07 |
emim 2021 |
PS 11-06 |
emsot |
PS 06-03 |
endocarditis |
130 |
endoscopy |
177 177 PS 23-07 PS 09-07 125 |
enhanced permeability and retention (epr) effect |
125 #159 |
enzyme responsive mri contrast agent |
#250 |
epcam |
125 |
epilepsy |
PS 08-03 PS 21-03 128 |
epr effect |
PL 07 PL 06 |
eric |
#687 #688 |
esophageal cancer |
125 |
esophageal carcinoma |
PS 09-07 |
eurobioimaging |
#688 |
european research infrastructure consortium |
#687 #684 #751 |
ex vivo |
PS 23-07 128 |
ex vivo biodistribution |
104 |
exchange |
#57 |
exendin |
PS 09-07 #336 |
exfoliated graphene |
#487 |
exosomes |
109 128 #512 |
experimental autoimmune myocarditis |
130 |
extracellular lactate |
PS 06-04 |
f-18 |
#163 |
fap |
#132 |
farewell |
PS 11-06 |
fat correction |
111 |
fat deposition |
#385 |
fatty acid |
#206 |
fbp |
PS 01-03 |
fdg |
179 104 #45 |
fdg pet |
130 #424 |
feline oral squamous cell carcinoma |
192 125 |
ferrocene derivatives |
101 |
fexi |
#57 |
fibril orientation |
128 |
fibroblast |
#132 |
fibroblast activation protein |
PS 06-03 |
fibrosis |
#211 PS 23-04 #249 PS 01-04 PS 01-04 |
figure making |
PL 06 |
fine-tuning |
PS 01-02 |
fish |
#314 |
fkbp12-ryr stabilizer |
179 #291 |
fli |
177 PS 08-07 |
flim |
#265 |
flt-ct |
PS 05-04 |
fluorescein |
#465 |
fluorescein angiography |
109 |
fluorescence |
179 PS 23-07 PS 06-05 100 125 139 #178 #206 #165 #647 |
fluorescence imaging |
PS 04-04 |
fluorescence guided surgery |
139 |
fluorescence image-guided surgery |
179 PS 05-02 139 |
fluorescence imaging |
PS 05-04 PS 08-04 #583 PS 01-04 PS 24-02 |
fluorescence life-time imaging |
#329 |
fluorescence lifetime |
PS 23-07 |
fluorescence microscopy |
PS 09-03 PL 06 #275 |
fluorescence molecular tomography |
#223 |
fluorescence monitoring |
#67 |
fluorescence tomography |
PS 07-04 #504 |
fluorescence-guided surgery |
177 PS 23-07 PS 08-02 PS 24-02 #647 |
fluorescence-guided-surgery |
PS 24-02 |
fluorescent dyes |
#84 |
fluorescent imaging |
PL 06 |
fluorescent organic nanoparticles |
#112 |
fluorescent platform |
179 105 |
fluorescent probes |
#273 #388 |
fluorescent probes for in vivo in real-time imaging |
126 |
fluorescent proteins |
129 |
fluorine-18 |
192 PL 07 PL 07 #263 |
fluorogenic peptide |
126 |
fluorophores |
139 |
fluroine-18 |
PS 01-02 |
fmn |
#465 |
fmri |
PS 23-02 PS 23-02 PS 08-03 PS 09-03 PS 09-03 109 111 #461 PS 24-03 |
focused rf heating |
PS 23-03 |
focused-ultrasound |
PS 10-02 |
focussed ultrasound |
PS 09-02 |
formaldehyde |
#67 |
foundations |
PS 01-03 |
fret |
179 #178 #112 |
fugene |
105 |
full-wave inversion |
#401 |
fumarate |
PS 23-03 |
functional connectivity |
191 191 PS 22-03 PS 23-02 109 127 |
functional imaging |
#415 PS 24-03 |
functional mri |
#591 PS 08-03 #54 |
functional networks |
102 |
functional ultrasound |
191 109 109 #237 |
functional ultrasound imaging |
PS 23-02 |
fungal biofilm |
#257 |
fungal infection |
#257 |
fungal infection model |
129 |
fungal infections |
179 129 |
furimazine |
PS 08-02 |
gadolinium |
PS 01-02 #409 |
galectin-3 |
PS 05-02 101 |
gallium-68 |
177 PS 05-03 PS 08-07 PS 08-02 113 127 |
gangliosides |
PS 09-03 |
gastrin-releasing peptide receptor |
113 |
gastrointestinal |
179 PS 05-04 104 |
gbm |
PS 06-04 |
gcp ii ligands |
PL 06 |
gd(dota) nanoconstructs |
#506 |
gd-aaztac17 |
#570 |
gdept |
177 PS 08-07 |
genetic reporter systems |
104 |
giant |
#156 |
glial cells |
PS 01-05 |
glioblastoma |
PS 23-05 PL 06 125 126 #424 |
glioma |
PS 23-05 |
glp-1 receptor |
PS 09-07 #336 |
glucose |
PS 23-03 |
glucose metabolism |
128 |
glutamine |
PS 06-03 |
glutathione |
#165 |
glymphatic |
#413 #421 |
glymphatic system |
102 |
gold nanoclusters |
PS 05-04 |
gold nanoparticles |
101 111 |
gold-shell nps |
105 |
good manufacturing practice |
112 |
group beta streptococcus (gbs) |
129 |
grpr |
100 |
grpr-antagonist |
113 |
gszs |
#462 |
gvhd |
179 104 |
halotag |
128 |
hcc |
#495 |
head and neck cancer |
192 125 |
heart |
130 #686 |
heart failure |
#211 PS 23-04 PS 01-04 |
hemodynamics |
#405 |
hemoglobin |
#464 |
hepatitis |
104 |
heptamethinecyanine fluorescent dyes |
#487 |
her2 |
PS 18-04 |
her3 |
PS 18-04 |
het-cam |
192 113 |
hetcam |
113 |
heterocyclic-substituted bodipy derivatives |
#443 |
hgsoc |
PS 05-02 |
high field |
#305 |
high field mr |
#395 |
high field strength |
#391 |
high integration |
PS 22-03 |
high penetration depth |
PS 08-03 |
high rate pet |
PS 21-02 |
high resolution mri |
#357 |
high throughput imaging |
111 |
histology |
PS 08-02 |
hne |
179 #178 |
hormones |
#591 PS 08-03 |
hounsfield units |
111 |
human carotid artery |
PS 23-04 |
humanized fab |
PS 05-02 101 |
huntington's disease |
PL 05 102 |
hybrid |
#314 |
hybrid imaging |
PS 01-03 |
hybrid microscopy |
#726 |
hybrid pixel detector |
PS 08-03 |
hybrid-imaging |
172 |
hypercapnia |
#370 |
hyperglycemia |
127 |
hyperoxia |
#370 |
hyperpolarization |
PS 06-04 PS 06-04 PS 23-03 PS 23-03 #427 #465 PS 02-06 |
hyperpolarized |
178 PS 23-03 |
hyperpolarized 13c |
193 PS 22-03 #424 #252 PS 02-06 |
hyperpolarized mrsi |
#44 PS 02-06 |
hyperpolarized nmr |
#557 PS 02-06 |
hyperspectral |
178 PS 05-04 |
hypertension |
139 |
hypoparathyroidism |
111 |
hypoxia |
PS 23-04 PS 08-07 PS 09-02 PL 07 #404 |
idiopathic lung diseases |
PS 05-04 |
igdd |
#750 |
il-6 |
#461 |
illumination pattern |
PS 05-04 |
image derive arterial input function |
193 #457 |
image fusion |
PS 01-03 |
image processing |
178 PS 08-06 111 |
image quality |
PS 01-06 PS 22-03 |
image reconstruction |
193 PS 01-03 PS 01-03 PS 05-04 #148 #223 |
image registration |
111 |
image-guided drug delivery |
PS 06-03 125 #570 #159 |
image-guided therapy |
PS 01-04 |
imaging |
178 PS 05-02 PS 05-02 PS 23-03 PS 23-03 PL 07 #404 125 129 |
imaging biomarkers |
PS 06-03 PS 06-03 |
imaging guided biodistribution |
127 |
imaging mass spectrometry |
PS 01-05 |
imaging processing |
PS 05-04 |
imaging tumour cell death |
PL 05 |
imatinib |
191 103 |
immune cell imaging |
104 |
immune inflammation |
104 |
immune system |
#657 |
immune-cell targeting |
#536 #536 |
immuno-pet |
192 PS 05-03 PS 09-07 PL 07 #631 |
immuno-theranostics |
#654 |
immunocompetent models |
126 |
immunofluorescence |
168 |
immunomodulation |
#33 PS 21-03 |
immunopet |
PS 01-02 PS 05-02 PS 05-06 #151 #628 |
immunotherapy |
PS 19-03 PS 09-07 126 |
implant |
#54 |
implanted nmr microcoil |
PS 23-03 |
imultaneous pet/ct-uui system |
PS 21-02 |
in ovo |
113 |
in silico modeling |
PL 06 |
in vitro |
129 |
in vivo |
PS 09-07 #409 #59 |
in vivo bioluminescence |
179 129 |
in vivo cell tracking |
#13 |
in vivo clearance |
#583 |
in vivo confocal |
129 |
in vivo fluorescence imaging |
#13 #504 |
in vivo imaging |
PS 05-03 #583 |
in vivo micropet |
104 |
in vivo spectral unmixing |
#13 |
in vivo two-photon |
129 |
in-loop |
112 |
in-vivo |
PS 08-04 139 |
in-vivo imaging |
PS 21-02 |
in-vivo x-ray imaging |
PS 02-02 |
indium-111 |
105 |
indocyanine green |
PS 06-05 111 |
infarct |
PS 01-04 |
infection |
PS 05-06 PS 08-02 |
infection imaging |
130 129 129 |
infectious diseases |
129 |
inflammation |
#211 178 179 PS 06-04 PS 23-04 PS 08-04 #320 #321 PS 09-02 102 104 104 130 #178 #13 PS 01-04 |
inflammation imaging |
191 130 |
inflammtion |
PS 22-05 |
innate immunity |
#35 |
instruct-eric |
#723 |
insulinoma |
PS 09-07 |
integrin αvβ6 |
192 PL 06 |
integrins |
101 |
interness |
#588 |
interstitial-illumination |
PS 09-02 |
intra-operative imaging |
PS 05-02 PS 23-07 PS 23-07 139 |
intranuclear |
PL 07 |
intraoperative |
177 PS 23-07 PS 23-07 |
intraoperative imaging |
PS 05-02 PS 24-02 |
intraperitoneal kainic acid rat model |
102 |
intraperitoneal tumor model |
139 |
intravital microscopy |
#536 #536 |
intravital multiphoton microscopy |
177 PS 23-05 |
introductory lecture |
PS 05-03 |
introductory talk |
PS 23-07 PS 08-07 |
inverse problems |
PS 01-03 |
inversion recovery |
128 |
ionizing radiation |
130 |
ipsc-nps |
127 |
iron metabolism |
PL 06 |
iron oxide nanoparticles |
179 PL 06 #77 |
ischemia |
128 |
ischemia-reperfusion |
PS 21-03 |
ischemic stroke |
102 |
kem |
193 111 |
kidney |
#44 PS 02-06 |
kinetic modeling |
PS 06-04 |
kisspeptin |
128 |
kit-based infection imaging |
129 |
kp46 |
101 |
l-dopa induced dyskinesia |
PS 23-02 |
label-free |
PS 23-04 |
label-free molecular imaging |
PS 22-06 |
labeling |
PS 06-05 126 |
lanthanide complexes |
#317 |
large stokes shift |
PS 06-05 |
large vessel vasculitis |
103 |
laser spectroscopy |
PS 05-04 |
lc3 associated phagocytosis (lap) |
129 |
ldl |
#570 |
led |
#466 |
leucine |
102 |
life science research infrastructure |
#684 |
life sciences |
#687 #751 |
lifetime of fluorescence |
#267 |
light sheet |
#585 |
light sheet fluorescence microscopy |
125 #472 |
light sheet microscopy |
#372 |
light-triggered drug delivery |
#127 |
line scanning |
PS 09-03 |
lipid |
PS 23-04 |
lipid metabolism |
#456 |
lipids |
PS 08-03 PS 09-03 PL 06 |
liposome labelling |
112 |
liposomes |
PS 09-02 #156 #59 |
live-cell |
PS 22-06 |
liver |
PS 09-02 #13 #265 |
ln complexes |
105 |
localistion |
128 |
longitudinal in vivo micro-computed tomography |
103 |
lorentzian fitting |
111 |
low dose imaging |
PS 01-06 |
lps |
PS 08-03 |
lsfm |
PL 06 #394 #319 |
luciferin dose boost |
179 129 |
lung |
PS 08-06 |
lung ct |
PS 21-02 |
lung fibrosis |
#430 |
lung imaging |
#393 #249 |
lung ventilation |
PS 08-03 |
lymph node staging |
PS 09-07 |
lymphadenectomy |
PS 05-02 |
macaca fascicularis |
#416 |
machine learning |
PS 05-02 PS 08-07 PS 08-06 111 127 |
maco |
127 |
macrophage |
130 |
macrophage mannose receptor |
126 |
macrophage mannose receptor (mmr) |
192 126 |
macrophage polarization |
PL 06 |
macrophage profiling |
126 |
macrophages |
191 192 126 126 130 |
magnetic particle imaging |
126 |
magnetic resonance fingerprinting |
#391 |
magnetic resonance imaging |
PS 21-03 127 #613 PS 01-04 |
magnetic resonance spectroscopy |
176 PS 06-04 127 |
magnetization transfer contrast |
#156 |
malaria |
PS 05-06 |
maldi |
PS 08-03 #635 |
maldi-msi |
PS 23-04 100 |
malignant melanoma |
PL 06 |
manganese |
PS 23-04 #92 #462 |
manganese complexes |
#558 |
manganese ferrite |
105 |
manganese-52 |
112 |
mannose receptor |
PS 05-02 |
maps |
PL 06 |
mass spectrometry |
PS 01-05 168 |
mass spectrometry imaging |
PS 06-04 PS 09-03 #708 #635 |
material decomposition |
#255 |
mct1 |
PS 08-02 |
mcts |
#394 |
mdsfr/sff spectroscopy |
111 |
mechanical force |
PL 06 |
mechanical ventilation |
PS 08-06 |
medical imaging |
PS 05-03 |
melanin |
#314 |
melanocytic nevi |
PL 06 |
melanoma |
PL 07 100 |
memory |
PS 24-03 |
mesenchymal stem cells |
128 #512 |
mesoporous silica nanoparticles |
PS 06-05 |
metabolic |
PS 05-02 |
metabolic changes |
127 |
metabolic disease |
#456 |
metabolic imaging |
PL 05 #265 |
metabolic profiling |
PS 23-03 |
metabolism |
176 PS 22-03 PS 06-04 PS 06-04 PS 06-04 PS 23-03 PS 23-03 #427 #618 PS 02-06 |
metal airborne particles |
PS 05-04 |
metal doping |
179 #77 |
metallomics |
PS 05-03 |
metastases |
192 PL 06 |
mhtt |
PL 05 |
micro-ct |
PS 10-02 PS 21-02 PL 07 #25 #576 |
microalgae radiolabelling |
#45 |
microbubbles |
PS 05-02 #127 |
microct |
PS 01-05 PS 23-04 #430 #249 |
microct imaging |
#20 |
microfluidics |
PS 08-04 112 |
microglia |
#301 |
micromechanics |
PS 08-06 |
micropet |
PS 01-05 |
micropet/ct |
PL 06 |
microscopy |
#726 PS 05-04 #267 #314 |
microviscosity |
#267 |
mid-infrared |
PS 22-06 |
middle cerebral artery occlusion |
102 |
milabs vect/or/ct |
PS 07-04 |
minflux |
PS 22-06 |
mitochondria |
130 |
mitosis |
PL 06 |
mitoxantrone |
PS 06-05 |
mn2+ alternatives to gd3+ |
#588 |
modeling |
#421 |
models of sterile inflammation |
104 |
moderate severity stroke model |
191 127 |
molecular design |
PS 05-06 |
molecular fluorescence guided imaging |
PS 23-07 |
molecular imaging |
192 PS 22-03 PS 22-05 PS 08-07 100 103 119 #415 111 #165 |
molecular modeling |
#301 |
molecular pet imaging |
PS 18-04 |
molecular rotors |
#267 |
molecular vectors |
111 |
monoclonal antibodies |
#631 |
monocytes |
104 |
monte carlo |
111 #585 |
monte carlo simulations |
#181 |
motion compensation |
PS 02-02 |
motion correction |
193 PS 21-02 #457 |
motor task |
PS 23-02 |
mouse |
191 109 |
mouse model |
191 PS 05-06 128 128 |
mouse models |
#704 |
mpi |
126 |
mpo |
#35 |
mr-angiography |
#374 PS 05-06 |
mri |
#211 #33 192 PS 01-02 PS 01-03 PS 01-05 PS 01-05 PS 22-03 PS 23-06 PS 18-06 168 PS 05-06 PS 23-03 PS 23-04 PS 08-04 PS 08-04 #320 PS 21-03 PS 21-03 PS 21-03 PS 09-07 #127 PS 09-03 100 101 101 101 102 111 111 113 113 #413 #421 #416 127 128 128 128 #464 #558 #317 #216 #156 #506 #329 PS 24-03 |
mri cas |
#588 |
mri contrast agents |
105 #317 |
mri contrastagent |
#250 |
mri probes |
PS 08-04 |
mri signal amplification |
#250 |
mri-guided therapy |
101 |
mri/pet dual probes |
105 |
mrs |
PS 08-04 PS 08-03 104 111 |
mrs and mri |
PS 23-03 |
mrsi |
192 193 #424 #212 #252 PS 02-06 |
msi |
#618 #686 |
msot |
PS 04-04 PS 08-03 #404 |
multi modality imaging |
#357 |
multi-atlas |
109 |
multi-modal imaging |
168 PS 08-03 |
multi-photon microscopy |
PS 24-03 |
multidrug resistance |
PL 06 #275 |
multimodal imaging |
PS 07-04 168 PS 08-04 PS 08-03 #92 #84 100 105 #223 #635 |
multimodal microscopy |
168 |
multimodality |
#54 |
multimodality imaging |
101 |
multiphoton microscopy |
#265 |
multipinhole spect |
119 119 |
multiple sclerosis |
102 128 |
multiplexed imaging |
#257 |
multiplexing |
PS 08-07 |
multispectral |
177 177 PS 23-07 PS 09-07 |
multispectral optoacoustic tomography |
PS 08-06 |
myelin |
102 128 |
myocardial imaging |
119 |
myocardial infarction |
PS 09-02 130 PS 01-04 |
myocarditis |
130 |
myocardium |
PS 23-04 |
nano-radiomaterials |
#40 |
nanobodies |
192 PL 07 126 126 #654 |
nanobody |
176 PS 05-02 PS 05-02 |
nanodiamonds |
100 |
nanodroplets |
176 PS 06-05 |
nanofluorides |
PS 08-04 |
nanoluc complementation |
PS 08-02 |
nanomedicine |
#536 PS 06-03 #536 #40 125 #159 |
nanomedicines |
125 |
nanomicelles |
PS 08-04 |
nanomotors |
PS 05-03 |
nanoparticle |
PL 07 PL 06 #628 |
nanoparticle delivery |
PL 06 #275 |
nanoparticle labeling |
105 |
nanoparticles |
PS 08-04 105 105 113 #233 |
nanovesicles |
#112 |
nash |
#495 104 |
near infrared |
#440 #585 |
near infrared optical tomography |
#223 |
near-infrared fluorescence |
PS 05-02 |
near-infrared fluorescence imaging |
139 |
near-infrared imaging |
103 |
near-infrared probe |
PS 06-05 |
necrosis |
177 PS 06-03 |
necrosis imaging |
112 |
neoadjuvant therapy |
PS 09-07 |
neocardina |
#372 |
network analysis |
#461 |
network stabilization |
191 127 |
neurobehavior |
127 |
neuroblastoma |
PS 09-07 |
neurodegeneration |
109 |
neuroendocrine tumors |
#700 |
neuroimaging |
176 191 PS 01-05 172 PS 06-04 102 109 PS 24-03 PS 24-03 |
neuroinflammation |
PS 01-05 PS 09-03 #301 |
neuron cells |
109 |
neuronal cell cultures |
127 |
neuropeptides |
128 |
neuroprotection |
PS 21-03 |
neuroradiology |
PS 01-05 |
neurotensin |
177 PS 08-02 113 113 |
neurovascular coupling |
PS 23-02 PS 24-03 |
nevi |
100 |
new tracer |
113 |
nir-ii contrast agent |
PS 08-07 |
nirf |
PS 23-07 #151 |
nitrosative stress |
130 |
nk1 receptors |
127 |
nmrd |
176 PS 08-04 |
nodal metastasis |
PS 23-07 |
non-invasive |
PS 09-02 |
non-invasive imaging |
PS 09-03 128 |
non-linear imaging |
#385 |
nonhuman primate |
129 |
novel pre-clinical imaging applications |
PS 07-04 |
novel theranostic probes |
#216 |
nsclc |
113 |
ntr |
177 PS 08-07 |
ntsr1 |
100 |
nuclear imaging |
104 139 |
nuclear medicine |
PS 22-05 |
nuclear morphology |
111 |
numerical simulation |
PS 05-04 |
oatp |
PS 06-05 |
occupational exposure |
PS 05-04 |
oncocardiology |
130 |
oncology |
PS 24-02 |
onolytic virus |
PS 08-02 |
open access |
#687 #688 |
open access policy |
#726 |
optical |
PS 01-05 #249 |
optical clearing |
#329 |
optical control |
PS 05-06 |
optical imaging |
179 PS 05-04 PS 08-02 #84 100 105 #181 #440 #267 PS 24-02 |
optical imaging fluorophores |
192 101 |
optical imaging probe |
139 |
optical molecular imaging |
PS 08-02 |
optical projection tomography |
#472 |
optics |
PS 05-04 |
optimization |
PS 05-04 |
opto-acoustic |
100 |
optoacoustic |
PS 06-03 PS 08-03 PS 09-02 |
optoacoustic bio-imaging |
PS 04-04 |
optoacoustic imaging |
PS 23-05 103 #456 |
optoacoustic microscopy |
PS 22-06 |
optoacoustic techniques |
#405 |
optoacoustic tomography |
PS 06-03 109 #404 128 |
optoacoustics |
193 PS 08-07 PS 08-06 #58 #415 #360 |
optogenetics |
PS 09-03 PS 09-03 |
orthotopic glioblastoma model |
PL 06 |
orthotopic mouse model |
125 |
orthotopic xenograft |
PS 05-02 |
osem |
PS 01-03 |
osimertinib |
113 |
ovarian cancer |
PL 07 PL 06 101 125 #714 |
oxidative stress |
130 |
oxidized low-density lipoprotein |
103 |
oxygen |
#464 |
oxygenation |
#415 |
oxygenation-sensitive mri |
#370 |
p-selectin |
178 #321 PS 09-02 104 |
p2y12 receptor |
#301 |
paclitaxel |
#570 |
paediatric |
111 |
pah |
PS 23-04 |
pain chronification |
#461 |
palmitic acid |
#206 |
pan-cancer |
100 |
pancreas |
PS 08-02 |
pancreatic cancer |
179 192 PS 08-02 PL 07 PL 06 113 139 |
pancreatic ductal adenocarcinoma |
PS 06-03 |
paracest |
#317 |
parahydrogen |
PS 23-03 |
parallel transmit rf coil arrays |
PS 23-03 |
parathyroid hyperplasia |
112 |
parkinson's disease |
PS 01-05 PS 23-02 128 |
parkinson`s disease |
PL 05 |
parp |
192 100 #163 |
partial volume effect correction |
193 #457 |
partial wave spectroscopy |
PL 07 |
pathogenesis |
PS 05-06 |
pathomechanism |
130 |
patient-derived xenograft |
PS 05-02 |
patient-derived xenografts |
PS 23-05 |
pd-l1 |
176 PS 18-04 PS 05-02 |
pdac |
192 193 113 #212 #252 PS 02-06 |
pdac cancer |
PL 07 |
peg-spacer |
113 |
pentixafor |
PS 22-05 |
pentixather |
PS 22-05 |
perfusion |
112 #404 |
peripheral arterial disease |
#405 |
peripheral vascular disease |
#405 |
peristaltism |
PL 06 |
permeability |
#57 |
perylene diimide |
PS 06-05 |
pet |
#211 177 177 191 191 192 192 192 PS 01-03 PS 01-05 PS 01-05 PS 22-03 PS 22-05 PS 22-05 PL 05 168 PS 23-05 PS 05-03 PS 05-03 PS 06-04 PS 06-03 PS 06-03 PS 23-04 PS 08-03 PS 08-03 #320 #495 PS 08-02 PS 09-07 PS 09-03 PL 07 PL 07 PL 06 100 100 102 103 112 112 113 113 128 128 130 130 129 #212 #59 #45 #512 #714 #618 |
pet imaging |
176 176 179 179 PS 01-05 PL 05 PS 05-02 PS 05-03 PS 23-02 PS 23-04 #35 PS 09-07 PL 07 100 112 113 113 #301 128 139 #336 #205 |
pet imaging. |
PS 05-03 |
pet infection imaging |
129 |
pet tracer |
128 |
pet-ct |
179 PS 08-03 129 #291 |
pet-mr |
PS 21-02 |
pet-mri |
172 PS 05-02 PS 21-03 128 |
pet/ct |
177 192 192 193 PS 01-03 PS 01-06 PS 08-07 PL 06 100 104 119 126 |
pet/ct imaging |
#536 #536 |
pet/ct-imaging |
PS 05-02 |
pet/fmri |
PS 23-02 |
pet/mr |
193 PS 01-03 PS 21-02 111 |
pet/mri |
176 193 PS 01-06 PS 22-03 PS 22-03 172 PS 08-03 PS 08-02 #303 104 105 105 119 |
pet/spect |
PL 07 PL 07 |
ph imaging |
111 #613 #44 PS 02-06 |
ph sensor |
#317 |
phantom |
PS 09-02 #360 |
phantoms |
#560 |
pharmacokinetic |
111 |
pharmacokinetics |
179 PS 06-03 #291 |
pharmacology |
191 109 |
phase contrast imaging |
PS 21-02 PS 02-02 |
phase i |
192 126 |
phase iii |
PS 24-02 |
phase iii studies |
#647 |
phase mapping |
PS 21-03 |
phase retrieved tomography |
#472 |
phase-contrast |
109 |
phasecontrast |
PS 08-02 |
phenotyping |
#704 |
phosphine |
112 |
phospolipids |
PS 08-04 |
photo-cidnp |
#465 |
photo/optoacoustic |
126 |
photoacoustic |
PS 06-05 #466 #440 #314 |
photoacoustic imaging |
178 PS 06-05 PS 08-06 PS 09-02 #560 #150 |
photoacoustic imaging. |
PS 09-02 |
photoacoustics |
193 PS 09-02 103 #58 #415 #456 |
photocage |
#67 |
photochemistry |
PS 05-03 |
photocontrollable proteins |
PS 08-07 |
photodynamic therapy |
PS 06-03 #132 125 125 |
photoimmunotherapy |
PS 23-05 |
photon counting |
PS 02-02 |
photon-counting |
#25 |
photon-counting micro-ct |
#255 |
photopharmacology |
PS 05-06 |
photoradiolabelling |
176 PS 05-03 |
photosensitizer |
125 |
pituitary adenoma |
177 PS 23-07 |
pla-nanoparticles |
#216 |
placenta |
#464 |
plasmodium |
PS 05-06 |
platform |
#151 |
plga |
#583 |
polarization second harmonic generation |
100 |
polarization sensitive shg |
128 |
polidentate chelators |
179 112 |
poly-histidine |
103 |
polychromatic |
193 #148 |
polymer contrast agent |
#613 |
polymer-in-oil material |
PS 09-02 |
polymeric nanoparticles |
PS 08-04 |
polypept(o)ide stars |
125 |
polypyrrole nanoparticles |
#150 |
porphyrins |
112 |
positon emission tomography |
102 |
positron emission tomography |
PS 01-05 PS 01-06 PS 08-07 #84 PL 06 104 112 113 #263 128 130 |
pre-clinical |
127 |
pre-resonance |
178 PS 05-04 |
precision medicine |
PS 23-05 125 |
preclincal imaging |
#658 |
preclinical |
PS 01-06 PS 22-03 111 |
preclinical computed tomograpy |
111 |
preclinical imaging |
193 PS 05-04 PS 06-05 105 119 |
preclinical pet |
PS 08-06 PS 21-02 |
preclinical pet insert |
PS 21-02 |
preclinical spect |
119 |
preclinical studies |
#263 |
preclinical trials |
125 |
pretargeting |
192 PL 07 |
primate |
PS 23-02 |
probe chemistry |
#395 |
probes |
PS 05-03 |
projections |
#319 |
prostae & pancreas |
#462 |
prostate cancer |
PS 23-07 100 101 113 #700 |
proste cancer |
100 |
protein synthesis rate |
102 |
proteins |
PS 09-02 |
proton therapy |
176 PS 06-05 |
prrt |
101 |
psma |
172 PL 06 100 101 105 113 #700 |
pulmonary airways |
178 PS 21-02 |
pulmonary arterial hypertension |
PS 23-04 |
pulmonary fibrosis |
#576 |
pulmonary hypertension |
#205 |
pyclen derivatives |
#558 |
q175 mouse model |
102 |
quality control |
PS 01-06 |
quantification |
193 PS 08-06 119 111 |
quantitation |
139 |
quantitative mri |
#391 |
quantitative photoacoustic tomography |
#360 |
quantitave |
193 #148 |
quasi-periodic patterns |
102 |
radiation-induced nucleation theory |
176 PS 06-05 |
radio-contrast agents |
#222 |
radio-iodine |
PS 01-02 |
radiochemistry |
PS 05-03 PS 08-07 #59 #407 |
radiofluorination |
179 112 |
radiofrequency ablation |
PS 09-02 |
radiolabeling |
105 113 |
radiometal |
PS 01-02 |
radiomics |
103 |
radionuclide |
PS 23-07 |
radionuclide imaging |
PS 01-02 |
radionuclide therapy |
101 |
radionuclides |
PS 01-06 |
radiosynthesis |
#346 |
radiotracer |
PS 05-06 |
radiotracers |
PS 01-05 |
range verification |
176 PS 06-05 |
rasp |
PS 09-02 |
rat |
PS 23-02 PS 23-04 PS 08-03 128 |
ratiometry |
PS 08-04 |
recombinant proteins |
103 |
recovery |
191 102 |
rectal cancer |
172 |
redox-sensitive |
#165 |
regularization |
PS 05-04 |
relaxivity |
PS 01-02 |
remote ischemic conditioning |
PS 21-03 |
remyelination |
191 #46 |
renal |
PS 23-03 |
reporter gene |
128 |
reporter genes |
PS 18-06 |
reporting |
PS 01-06 |
research infrastructure |
#688 #723 #704 #726 |
research infrastructures |
#687 #751 |
resistance |
PL 07 #714 |
resolution modeling |
PS 01-03 |
respiratory gating |
PS 22-03 |
respiratory system |
103 |
response to therapy |
177 PS 06-03 |
responsive agents |
#462 |
responsive contrast agent |
#11 |
resting state |
191 PS 23-02 PS 08-03 109 109 #461 |
resting state fmri |
#325 191 PS 23-02 PS 08-03 127 |
resting state functional mri |
102 |
retention |
#409 |
retina |
128 |
rf coil design |
#305 |
rhenium |
112 |
rheumatoid arthritis |
#132 |
rhodobacter |
126 |
riboflavin |
125 |
rnaseq |
PL 06 |
rodent |
109 |
ros |
#35 112 |
rotenone mouse model of parkinson's disease |
102 |
rs-fmri |
191 #46 |
rsfmri |
102 |
s. aureus |
130 |
safir |
PS 21-02 |
sah |
127 |
sample collection |
PL 06 |
scaffold characterization |
128 |
scinitgraphic |
#233 |
scintillator crystal |
119 |
segmentation |
109 111 |
selective targeting |
105 |
semiquantification |
PS 08-06 |
sensory stimulation |
109 |
serotonin transporter |
PS 23-02 |
sgm-101 |
PS 24-02 |
shift reagent |
PS 06-04 |
short term modulation |
PS 23-02 |
shortwave infrared fluorescence |
PS 05-04 |
siderophore |
129 |
siderophores |
129 |
sigma-1 receptor |
PL 06 |
signal processing |
PS 01-03 |
silica nanoparticles |
105 |
simulation |
#585 |
simulations |
111 |
simultaneous |
PS 22-03 |
simultaneous 3pef and 2pef microscopy |
109 |
simultaneous pet-mri |
PS 22-03 |
simultaneous pet/ct-uui system |
193 #457 |
simultaneous pet/mri |
PS 22-03 105 |
single molecule localization |
PS 22-06 |
single molecule tracking |
PS 22-06 |
single voxel 1h spectroscopy |
127 |
single-domain antibody |
139 |
site-specific |
176 PS 05-02 #151 |
site-specific bioconjugation |
103 |
skin cancer |
PL 06 |
sliding window analysis |
102 |
slow waves |
PS 09-03 PS 09-03 |
small animal |
PS 01-06 |
small animal imaging |
PS 01-06 #690 |
small animal mri |
#305 |
small animal pet |
PS 21-02 |
small molecule donor |
#67 |
small molecules |
#749 |
small-animal imaging |
119 |
small-animal spect |
119 |
smart contrast agent |
#395 |
smart probes |
#588 |
smartphone ophthalmoscope |
109 |
smartprobe |
179 #178 |
smartprobes |
#257 |
sodium |
PS 23-03 |
software-pipeline |
172 |
somatostatin receptor |
PS 23-07 |
sonopermeation |
192 125 |
sonoporation |
101 |
spect |
179 PS 01-03 PS 01-06 PS 07-04 PS 08-07 105 112 112 |
spect/ct |
192 PS 01-03 PS 08-03 PL 06 104 111 |
spect/ct imaging |
#233 |
spect/mri |
#374 PS 05-06 |
spectroscopic ct |
PS 08-03 |
spectroscopy |
176 PS 06-04 PS 09-02 |
speed-of-sound |
#401 |
spheroids |
PL 07 PL 07 101 |
spill-in effect |
PS 08-06 |
spim |
#319 #372 |
spinal cord injury |
128 |
spion |
105 |
spline |
111 |
spm |
PS 08-06 |
spondyloarthritis |
104 |
sstr |
#700 |
stability |
#588 |
standardisation |
#560 |
standardization |
#658 #690 |
staphylococcus aureus |
PS 05-06 |
stem cells |
PS 23-06 PS 06-05 105 105 |
stent graft infections |
129 |
stimulated raman scattering |
178 PS 05-04 |
strain |
PS 08-06 |
stroke |
#33 191 PS 06-04 PS 21-03 PS 21-03 102 109 127 127 |
stroke model |
PS 21-03 |
stroke-induced hyperconnectivity |
191 127 |
study group |
#738 PS 24-04 PS 24-04 PS 24-04 PS 24-04 |
su5416 |
PS 23-04 |
subarachnoid haemorraghe |
127 |
subcutaneous tumor xenografts |
#329 |
sultone |
PL 07 |
super resolution |
PS 06-05 |
super resolution fluorescence imaging |
PS 22-06 |
super resolution in cardiac pet |
PS 21-02 |
super resolution optical microscopy |
PS 22-06 |
super-resolution microscopy |
129 |
superparamagnetic nanoparticles |
105 |
superresolution |
178 PS 09-03 |
surgical imaging |
PS 24-02 |
surgical inovation |
PS 24-02 |
surgical margin assessment |
193 #197 |
susceptibility-weighted imaging |
PS 21-03 |
sv2a |
191 128 |
swir imaging |
PS 08-07 |
synaptic density |
191 102 128 |
synchrotron imaging |
#393 |
synchrotron radiation |
178 PS 21-02 PS 21-02 |
synthesis |
PS 06-05 |
synthesis and characterization |
#443 |
synthetic biology |
PS 18-06 |
synuclein |
#222 |
system performance |
PS 01-06 |
system xc- |
PS 08-07 |
t-cell lymphoma |
PS 06-04 |
t1 contrast |
179 #77 |
t1-mri |
#40 |
t1-weighted 3d mr |
127 |
takotsubo syndrome |
130 |
tam |
126 |
target-to-background ratio (tbr) |
PS 08-06 |
targeted |
105 |
targeted alpha-particle therapy |
101 |
targeted drug delivery |
PS 23-03 125 |
targeted hyperthermia |
PS 23-03 |
targeting |
PS 08-04 105 #156 |
tau |
PS 01-05 PS 21-03 |
tc-99m |
130 |
tca cycle |
#557 PS 02-06 |
technetium-99 |
112 |
technical validation |
PS 09-02 |
temporal lobe epilepsy |
102 |
tetrazoles |
PS 05-03 |
tgf-beta |
PS 18-04 |
thalamus |
#416 |
thallium |
#407 |
theranostic |
PS 07-04 125 |
theranostic agents |
105 |
theranostic probes |
192 101 |
theranostics |
179 PS 22-05 PS 22-05 172 PS 05-06 PL 07 105 125 #748 #700 #747 #749 |
therapeutic biologicals |
#631 |
therapy |
127 |
thermogenic activator |
PS 06-04 |
third harmonic generation |
100 |
third harmonic generation (thg) |
#385 |
thn201 |
#237 |
thp |
#59 |
thrombectomy |
PS 21-03 |
thyroid cancer |
PS 05-02 PS 23-07 101 |
thyroid surgery |
111 |
time-lapsed tomography |
PS 01-06 |
tissue distribution |
193 119 |
tissue implants |
176 PS 08-04 |
tissue-mimicking material |
PS 09-02 |
tof-kem |
193 111 |
tof-pet |
193 119 111 |
tof-sims |
#265 |
toll-like receptors |
102 |
tomographic microscopy |
#319 |
tomographic optical and morphological imaging |
PS 08-02 |
tomography |
193 PS 08-02 #58 #401 |
translational |
111 |
translational imaging |
PS 21-03 |
translational medicine |
#684 |
translational research |
#25 |
transparent pet |
PS 22-03 |
transverse electron microscopy |
105 |
treatment response |
PS 06-03 |
trifluoromethylation |
#346 |
trigger-responsive |
PS 01-02 |
trimodal nanosystems |
105 |
tris (8-hydroxyquinolinato) gallium (iii) |
101 |
tsne |
PS 08-03 |
tspo |
179 PS 08-06 130 139 |
tumor |
126 |
tumor acidosis |
176 #303 #613 |
tumor imaging |
113 |
tumor invasion |
177 PS 23-05 |
tumor markers |
139 |
tumor microenviroment |
#329 |
tumor microenvironment |
177 PS 23-05 PS 23-05 PL 06 125 #159 |
tumor microenvironment heterogeneity |
PL 06 #275 |
tumor microenvironment ph |
PS 08-07 |
tumor profil |
PL 06 |
tumor targeting |
PS 06-03 |
tumor-associated macrophages |
126 |
tumor-associated-macrophage |
126 |
tumor-homing phagocytes |
#536 #536 |
tumors |
PS 05-02 |
tumour |
178 PS 23-03 PL 06 111 |
tumour microenvironemnt |
PS 06-04 |
tumour vascularisation |
PL 06 |
tuning photophysical properties |
#443 |
turbid media |
PS 05-04 |
two-photon microscopy |
PS 24-03 |
u-spect5 e-class |
119 |
ucb-h |
102 |
ultra-high field mri |
PS 23-03 |
ultrafast imaging |
178 PS 09-03 |
ultrafast ultrasound |
PL 06 |
ultrafast ultrasound imaging |
130 |
ultrasmall nanoprobes |
105 |
ultrasound |
178 178 PS 18-06 168 PS 05-02 #127 PS 09-03 PS 09-02 PS 09-02 101 #401 #466 PS 24-03 PS 24-03 |
ultrasound image processing |
100 |
ultrasound imaging |
139 PS 01-04 |
ultrasound molecular imaging |
178 #321 PS 09-02 |
ultrasound therapy |
101 |
ultrasound-guided injection |
PL 07 |
usmb |
192 125 |
uspio |
PS 09-07 |
validation |
111 |
vap-1 |
130 |
vascular disorder |
PS 05-04 |
vascular permeability |
#506 |
vasculature |
PS 23-05 |
vasoreactivity |
#370 |
vector |
PS 01-02 |
vector6 pet |
PS 07-04 |
vessels |
PL 06 |
vevolazr-x |
PL 07 125 |
vhh |
PS 08-07 |
viability |
PS 23-04 |
volumetric imaging |
PS 24-03 |
voxel-by-voxel analysis |
PS 08-03 |
water-soluble aza-bodipy |
PS 08-07 |
welcome |
#745 |
western diet |
PS 08-03 |
white matter |
#416 |
white matter hyperintensities |
111 |
whole body |
PS 01-06 |
x-nuclei |
#305 |
x-ray |
PS 08-02 |
x-ray & optical ct |
PS 07-04 |
x-ray computed tomography |
178 PS 21-02 |
x-ray imaging |
111 PS 02-02 |
x-ray imaging study group |
PS 02-02 |
x-ray tomography |
193 PS 22-06 109 #148 |
xenograft |
192 113 |
xlf |
#430 |
yia |
PS 11-06 |
zebrafish |
PS 21-02 #20 |
zinc sensors |
#462 |
zirconium-89 |
176 PS 05-03 #628 #631 |
zirconium[89] |
PS 05-06 |
zymonic acid |
#44 PS 02-06 |
α1-microglobulin |
101 |
α4β2 nicotinic acetylcholine receptor |
102 |
fluorescence microscopy |
105 |